Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery...

Area of Science:

• Cardiology
• Cardiac Surgery
• Pharmacology

Background:

• Myonecrosis post-coronary artery bypass graft (CABG) surgery is a significant predictor of mortality.
• Tranexamic acid (TA), an anti-fibrinolytic, is used to reduce blood loss but its effect on post-CABG myonecrosis is not well-established.
• Previous studies suggest TA does not increase myocardial infarction (MI) risk.

Purpose of the Study:

• To investigate the association between tranexamic acid (TA) treatment and myonecrosis following CABG surgery.
• To evaluate the impact of TA on 30-day cardiovascular death or MI in CABG patients.

Main Methods:

• A trial involving 656 patients receiving TA and 770 not receiving TA.
• Inverse probability weighting of propensity scores was used to adjust for confounding factors.
• Primary outcome: creatine kinase MB (CK-MB) area under the curve (AUC) at 24 hours.
• Secondary outcome: 30-day incidence of cardiovascular death or MI.

Main Results:

• Patients receiving TA had a higher median 24-hour CK-MB AUC (301.9 vs 253.5 ng·h/mL, p < 0.001), indicating increased myonecrosis.
• No significant difference was observed in the 30-day incidence of cardiovascular death or MI between the TA and no-TA groups (8.7% vs 8.3%, adjusted OR 0.99; 95% CI 0.67-1.45).
• TA-treated patients were more likely to be female and have pre-existing conditions like heart failure or previous MI.

Conclusions:

• Tranexamic acid (TA) administration in CABG patients is associated with a higher risk of myonecrosis.
• TA treatment did not increase the risk of 30-day cardiovascular death or myocardial infarction.
• Further research is needed to understand the pathophysiology of TA-induced myonecrosis and its clinical implications.